Philogen Collaborates with Johnson&Johnson (J&J), Novartis and Celgene

 Philogen Collaborates with Johnson&Johnson (J&J), Novartis and Celgene

Philogen Collaborates with Johnson&Johnson (J&J), Novartis and Celgene

Shots:

  • Philogen collaborates with J&J to discover & develop therapies utilizing Philochem’s technology (a Swizz subsidiary of Philogen) for serious conditions
  • Philogen signs a development and commercialization agreement with Celgene for novel immunomodulatory therapies
  • Philogen collaborates with Novartis for the research and development of immunomodulatory candidates. In 2017 & 2016, Philogen also collaborated with Boehringer Ingelheim (BI) and Pfizer to develop and commercialize DNA-encoded therapies & ADCs for multiple therapy areas respectively

Click Here  read full press release/ article | Ref: Philogen | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post